Evidence map›Paper›PMID 42263262›Full record

ArticleJournal of medicinal chemistry2026

Development and Preclinical Evaluation of

Fengsheng Zhang, Jindian Li, Dongliang Wang, Xuwei Liu, Xiaoyu Pan, Simin He, Jianping Zhang, Hao Shen, Shaoli Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Fengsheng ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jindian LiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0009-0004-1113-6760
Dongliang WangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xuwei LiuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Xiaoyu PanDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Simin HeDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Jianping ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Hao ShenInstitute of Modern Physics, Fudan University, Shanghai 200433, China.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai 200032, China.ORCID 0000-0003-2544-7522

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B7-H3 (CD276) is an emerging target for cancer theranostics, highlighting the need for imaging probes capable of noninvasively quantifying B7-H3 expression in tumors. Here, we developed three

Indexed as

B7 AntigensGallium RadioisotopesPeptides, CyclicRadiopharmaceuticalsAnimalsCell Line, TumorHumansMicePositron-Emission TomographyPositron Emission Tomography Computed TomographyTissue DistributionB7 AntigensCD276 protein, humanGallium-68Gallium RadioisotopesPeptides, CyclicRadiopharmaceuticals68GaB7-H3bicyclic peptidePET/CTsolid tumor

Identifiers

PMID42263262
PMCPMC13313057

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.